N@N

Naz Rahman Downgraded (VRTX) to Hold on, Jan 31st, 2024

Naz Rahman of Maxim Group, Downgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Hold on, Jan 31st, 2024.

Naz has made no other calls on VRTX in the last 4 months.

There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 3 agree with Naz's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Brian Abrahams of "RBC Capital" Maintained at Hold with Increased Target to $379 on, Thursday, December 14th, 2023
• Paul Matteis of "Stifel" Reiterated at Hold and Held Target at $373 on, Wednesday, November 22nd, 2023
• Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $364 on, Wednesday, November 8th, 2023

These are the ratings of the 6 analyists that currently disagree with Naz

---

• Olivia Brayer of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $440 on, Wednesday, January 24th, 2024
• Whitney Ijem of "Canaccord Genuity" Downgraded from Hold to Strong Sell and Increased Target to $379 on, Wednesday, January 24th, 2024
• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $397 on, Monday, December 11th, 2023
• Gena Wang of "Barclays" Maintained at Buy with Increased Target to $415 on, Monday, December 11th, 2023
• Evan Seigerman of "BMO Capital" Maintained at Buy with Increased Target to $415 on, Tuesday, November 7th, 2023
• Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $370 on, Tuesday, October 17th, 2023

Contributing Sources

---